Follow the guidance (if possible) [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2022-01-30 23:52 (116 d 15:43 ago) – Posting: # 22763
Views: 703

Hi Sereng,

» What are the sample size “benefits” or “efficiencies” of undertaking this study as a replicate CO design (e.g., Test 50 x 2; Ref 50 x 2) versus a 2-way CO (Test 100 x 2; Ref 100 x 2). Any help would be much appreciated.

None. In both cases you risk a Refuse-to-Receive because you deviate from the guidance (recommending the 20 µg strength administered as a 60 µg dose). Theoretically you could deviate from the guidance if you have good reasons for doing so and initiate a Controlled Correspondence. However, I think your chance is close to nil because the guidance offers the option of biowaivers for the strengths 13, 25, 50, 75, 88, 100, 112, 125, 137, 150, and 175 µg. Only if you can’t perform a study with the 20 µg strength – because you don’t have in your line of strengths – you can give it a try.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,108 posts in 4,630 threads, 1,567 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time: Friday 16:35 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5